IE41352B1 - 5-aryl-1,2,3,4-tetrahydro- -carbolines - Google Patents

5-aryl-1,2,3,4-tetrahydro- -carbolines

Info

Publication number
IE41352B1
IE41352B1 IE589/75A IE58975A IE41352B1 IE 41352 B1 IE41352 B1 IE 41352B1 IE 589/75 A IE589/75 A IE 589/75A IE 58975 A IE58975 A IE 58975A IE 41352 B1 IE41352 B1 IE 41352B1
Authority
IE
Ireland
Prior art keywords
group
general formula
reacting
tetrahydro
formula
Prior art date
Application number
IE589/75A
Other versions
IE41352L (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IE41352L publication Critical patent/IE41352L/en
Publication of IE41352B1 publication Critical patent/IE41352B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Abstract

1476087 5 - Phenyl - 1,2,3,4 - tetrahydro- γ-carbolines PFIZER Inc 26 March 1975 [1 April 1974] 12773/75 Heading C2C Novel 5 - phenyl - 1,2,3,4 - tetrahydro - γ- carbolines of the general Formula I wherein X is a hydrogen, fluorine, chlorine or bromine atom or a methyl group, Z is a hydrogen, fluorine or chlorine atom or a methoxy or trifluoromethyl group and R is a hydrogen atom, a C 1-6 alkyl or benzyl group, or a group of the Formula X in which A is a C 1-5 alkylene group, M is -CH = CH-, -CH 2 -, -CO-, -CH(OR 1 )- or -C(CH 3 )(OR 1 )-, where R 1 is a hydrogen atom or C 2-6 alkanoyl group, and K is a hydrogen, fluorine or chlorine atom or a methyl or trifluoromethyl group, with the proviso that when Z is a hydrogen atom, X is a fluorine, chlorine or bromine atom or a methyl group, and pharmaceutically acceptable acid addition salts thereof are prepared (a) when R is a hydrogen atom, by heating the corresponding ester of the general Formula III with ethanolic KOH; (b) when R is a C 1-6 alkyl or benzyl group or a group of the Formula X in which M is -CH 2 - or -CO-, by reacting the product of (a) with R-hal, wherein hal is a halogen atom or a sulphonate ester group; (c) when R is a C 1-6 alkyl group, by reacting a 1,2,3,4-tetrahydro-γ-carboline of the general formula with a Z-substituted bromobenzene in the presence of Cu 2 Br 2 and Na 2 CO 3 ; (d) when R is a C 2-6 alkyl group, by reducing the corresponding compound in which R is a C 2-6 alkanoyl group with a metal hydride; (e) when R is a methyl group, by reducing the ester of the general Formula III with LiAlH 4 or aluminium hydride; (f) when R is a group of the Formula X, by reacting a nitrile of the general formula with a Y-substituted phenyl magnesium halide; (g) when R is a group of the Formula X and M is -CH(OH)-, by reducing the corresponding compound in which M is -CO- with NaBH 4 ; (h) when R is a group of the Formula X and M is -C(OH)(CH 3 )-, by reacting the corresponding compound in which M is -CO- with CH 3 MgI; (i) when R is a group of the Formula X and M is -CH(OR 1 )- or -C(CH 3 )(OR 1 )-, in which R 1 is a C 2-6 alkanoyl group, by esterifying the corresponding compound in which M is -CH(OH)- or -C(CH 3 )(OH)-; and (j) when R is a group of the Formula X in which M is -CH = CH-, by dehydrating the corresponding compound M is -CH(OH)- and A is an alkylene group containing one more C atom than in the desired product, followed optionally by salification. Esters of the general Formula III are prepared by reacting a p-X-phenylhydrazine with N- ethoxycarbonyl-4-piperidone and reacting the resulting 2 - ethoxycarhonyl - 8 - W - 1,2,3,4- tetrahydro - γ - carboline with a Z - substituted bromobenzene in the presence of Cu 2 Br 2 and Na 2 CO 3 . Ketones of the general Formula I wherein R is a C 2-6 alkanoyl group are prepared by acylation of the corresponding compound in which R is a hydrogen atom. 1,2,3,4 - Tetrahydro - γ - carbolines of the general Formula IV are prepared by reacting a p-X-phenylhydrazine with a N-R-4-piperidone. Nitriles of the general Formula VI are prepared by reacting the corresponding compound I wherein R is a hydrogen atom with halogen- A-CN. Pharmaceutical compositions having tranquillizing activity comprise, as active ingredient, a novel 5-phenyl-1,2,3,4-tetrahydro-γ-carboline (I), wherein R is other than a hydrogen atom, or a pharmaceutically acceptable acid addition salt thereof, in admixture with a pharmacologically acceptable carrier. [GB1476087A]
IE589/75A 1974-04-01 1975-03-19 5-aryl-1,2,3,4-tetrahydro- -carbolines IE41352B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45664074A 1974-04-01 1974-04-01

Publications (2)

Publication Number Publication Date
IE41352L IE41352L (en) 1975-10-01
IE41352B1 true IE41352B1 (en) 1979-12-19

Family

ID=23813560

Family Applications (1)

Application Number Title Priority Date Filing Date
IE589/75A IE41352B1 (en) 1974-04-01 1975-03-19 5-aryl-1,2,3,4-tetrahydro- -carbolines

Country Status (6)

Country Link
JP (3) JPS5915911B2 (en)
BE (1) BE827451A (en)
CA (1) CA1056381A (en)
GB (1) GB1476087A (en)
IE (1) IE41352B1 (en)
ZA (1) ZA751990B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004063818A (en) 2002-07-30 2004-02-26 Oki Electric Ind Co Ltd Method for manufacturing semiconductor device using flexible tube
WO2011133224A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Organic compounds
EP2836213B1 (en) 2012-04-14 2018-07-04 Intra-Cellular Therapies, Inc. Fused gamma carbolines
PL2968320T3 (en) 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Organic compounds
KR102421656B1 (en) 2013-12-03 2022-07-15 인트라-셀룰라 써래피스, 인코퍼레이티드. Novel methods
KR20220054908A (en) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
WO2015154030A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
PT3407888T (en) 2016-01-26 2021-03-19 Intra Cellular Therapies Inc Organic compounds
PL3407889T3 (en) 2016-03-25 2021-11-22 Intra-Cellular Therapies, Inc. Organic compounds and their use in treating or preventing central nervous system disorders
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
CN110072518B (en) 2016-10-12 2021-10-26 细胞内治疗公司 Amorphous solid dispersion
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
JP7132939B2 (en) 2017-03-24 2022-09-07 イントラ-セルラー・セラピーズ・インコーポレイテッド Novel compositions and methods
CA3071119A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Organic compounds
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
CA3106447A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
MX2021002321A (en) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Novel methods.

Also Published As

Publication number Publication date
IE41352L (en) 1975-10-01
JPS5915911B2 (en) 1984-04-12
JPS5874682A (en) 1983-05-06
BE827451A (en) 1975-10-01
ZA751990B (en) 1976-02-25
GB1476087A (en) 1977-06-10
CA1056381A (en) 1979-06-12
JPS5874681A (en) 1983-05-06
JPS5874683A (en) 1983-05-06

Similar Documents

Publication Publication Date Title
IE41352L (en) 5-aryl-1, 2, 3, 4-tetrahydro-ô-carbolines
US4110383A (en) 2-Decarboxy-2-hydroxymethyl-3,7-inter-m-phenylene-.omega.-phenyl-PGA1 or 9-deoxy-9,10-didehydro-PGD1 compounds
US4083865A (en) Inter-oxa-13,14-dihydro-PGD1 compounds
US4124620A (en) Cis-4,5-didehydro-9-deoxy-PGD1 compounds
IE781473L (en) Pyrrolo-pyrrole-1-carboxylic acid derivatives
IE35424B1 (en) Cyclopropane derivatives
US4073797A (en) Sulphur containing derivatives
US4117233A (en) 2,2-Difluoro-13,14-didehydro-11-deoxy-17-phenyl-18,19,20-trinor-PGF2 α compounds
GB1488978A (en) 4-aryl-1,2,3,4-tetrahydropyrrolo(3,4-b)indoles
GB1493416A (en) Spasmolytics
US3564042A (en) Derivatives of acetic acid
GB1382267A (en) Phenylalkanoic acid derivatives
IE34427L (en) Alkenoic acid derivatives.
US4165325A (en) 11-Deoxy-trans-4,5,13,14-tetradehydro-PGI1 compounds
US4658033A (en) Synthesis of interphenylene prostaglandin analogs
GB1488904A (en) X-ray contrast media
GB1498377A (en) Alkyne derivatives and process for their preparation
GB1304951A (en)
US4317941A (en) 2-Decarboxy-2-hydroxymethyl-trans-2,3-didehydro-9-deoxy-9-methylene-PGF compounds
US4164502A (en) 2-Decarboxy-2-aminomethyl-trans-4,5,13,14-tetradehydro-PGI1 compounds
US3660579A (en) Derivatives of acetic acid in compositions and methods for the alleviation of hyperlipemia
GB1200981A (en) Novel bis-p-chlorophenoxy-acetic acid esters, the preparation thereof and compositions containing the same
GB1252131A (en)
IE34441L (en) Dibenzazepine derivatives
US3703560A (en) 3,4-diphenyl-1-(4-hydroxyphenyl)-cyclopentane